Key Developments: Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

2:00am EDT
Change (% chg)

¥120 (+3.30%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

ASKA Pharmaceutical to acquire manufacturing and marketing approval right of antithyroid drugs from Chugai Pharmaceutical
Friday, 3 Apr 2015 02:00am EDT 

ASKA Pharmaceutical Co Ltd:Signed a contract on April 3 to acquire manufacturing and marketing approval right of two antithyroid drugs from Chugai Pharmaceutical on Oct. 1.  Full Article

Athersys Inc and Chugai Pharmaceutical Co Ltd enter license agreement and collaboration to develop MultiStem Cell Therapy
Monday, 2 Mar 2015 06:00am EST 

Athersys Inc and Chugai Pharmaceutical Co Ltd:Says a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan.Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan's aging population.  Full Article

NanoCarrier signs joint research agreement with Chugai Pharmaceutical and to issue new shares
Tuesday, 24 Feb 2015 01:10am EST 

NanoCarrier Co Ltd:Signed a joint research agreement of siRNA drug with Chugai Pharmaceutical Co., Ltd.To issue 389,400 new shares to Chugai Pharmaceutical Co., Ltd. through private placement at 1,284 yen per share with amount of 499,989,600 yen.Payment date on March 12.Proceeds to be used as research and development expense of the joint research.  Full Article

Chugai Pharmaceutical to issue year-end dividend for FY 2014
Wednesday, 28 Jan 2015 02:30am EST 

Chugai Pharmaceutical Co Ltd:To issue a year-end dividend of 26 yen per share, for the FY ending Dec. 2014.Dividend issued to shareholders of record as of Dec. 31.Dividend payment date March 27.Says the dividend amount is above the latest forecast of 23 yen per share disclosed on Jan. 30, 2014.  Full Article

Chugai Pharmaceutical receives judgment of lawsuit
Thursday, 25 Dec 2014 01:00am EST 

Chugai Pharmaceutical Co Ltd:Received judgment of lawsuit from Tokyo District Court on Dec. 24.Filed a lawsuit against Iwaki Seiyaku Co.,Ltd, DKSH Japan K.K., POLA-Pharma and TAKATA SEIYAKU Co., Ltd. due to infringement of Chugai Pharmaceutical Co Ltd's patent of keratosis treatment agent (patent No. 3310301) of the four companies on Feb. 19, 2013.Judgment says provisional disposition instruction of import and sale injunction of the keratosis treatment agent for the four companies.  Full Article

Chiome Bioscience Inc announces joint research contract period extension with Chugai Pharmaceutical Co., Ltd.
Wednesday, 24 Dec 2014 01:00am EST 

Chiome Bioscience Inc:Announces joint research contract period extension to Dec. 31, 2015 with Chugai Pharmaceutical Co., Ltd.  Full Article

Chugai Pharmaceutical Co Ltd completes phase I results of Chugai’s Bispecific Antibody "ACE910" released at the American society of hematology meeting
Monday, 8 Dec 2014 10:00pm EST 

Chugai Pharmaceutical Co Ltd:Announces the phase I clinical data of anti-factor IXa x anti-factor X humanized bispecific antibody "ACE910," currently being developed for the indication of hemophilia A was presented at the 56th American Society of Hematology Annual Meeting on Dec. 8.Announces positive trial result on safety and efficacy of the ACE910.  Full Article

R&I affirms Chugai Pharmaceutical Co Ltd's rating at "AA-" and announces stable outlook
Wednesday, 1 Oct 2014 02:00am EDT 

Chugai Pharmaceutical Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-".Rating outlook stable.  Full Article

Zeltia SA's PharmaMar and Chugai Pharmaceutical Co Ltd's Chugai Pharma Marketing sign license agreement for Aplidin
Monday, 14 Jul 2014 05:31am EDT 

Zeltia SA:Says its subsidiary, PharmaMar SA, and Chugai Pharma Marketing Ltd, subsidiary of Chugai Pharmaceutical Co Ltd, signed license agreement.Under term of agreement, Chugai Pharma Marketing to market Aplidin in eight european countries (France, Germany, UK, Benelux, Ireland and Austria).Aplidin is PharmaMar product for treatment of multiple myeloma.PharmaMar to receive initial payment of 5 million euros and additional payments are also considered and could reach total number of more than 30 million euros.  Full Article

Chiome Bioscience Inc announces extension of co-research agreement with Chugai Pharmaceutical Co Ltd
Tuesday, 24 Dec 2013 01:00am EST 

Chiome Bioscience Inc and Chugai Pharmaceutical Co Ltd:Says the two companies have decided on extension of co-research agreement, to Dec. 31, 2014.  Full Article

Search Stocks